VTGN vs LCTX โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
LCTX Captures Institutional Edge (3โ1 Pillars ยท 9โ1 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Lineage Cell Therapeutics, Inc. (LCTX) driven by superior Valuation, Growth & Margin, Momentum & Technical while VTGN counters with relative strength in Options & Structure. Fundamentally, VTGN trades at N/M Forward P/E with -2543.1% operating margin (-46.5% YoY revenue) versus LCTX at 30.7x Forward P/E and -280.3% operating margin (-61.0% YoY). In options structure, VTGN sits in UNCLASSIFIED (71st %ile IV; Dealer Gamma Walls on Pro) against LCTX sits in BREAKDOWN (100th %ile IV; Dealer Gamma Walls on Pro).
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | VTGN Revenue | LCTX Revenue | VTGN Op. Margin | LCTX Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2019 | N/A | $0M | N/A | -1106.0% | LCTX |
| FY2020 | N/A | $0M | N/A | -1448.4% | LCTX |
| FY2021 | $0M | $0M | -1646.1% | -1133.6% | LCTX |
| FY2022 | $0M | $10M | -4308.3% | -153.2% | LCTX |
| FY2023 | N/A | $10M | N/A | -276.5% | LCTX |
| FY2024 | $0M | $10M | -3103.5% | -226.1% | LCTX |
| FY2025 | $0M | $10M | -11517.1% | -251.6% | LCTX |
| FY2026 | $0M | N/A | -5683.7% | N/A | VTGN |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | VTGN | LCTX | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $9.0M | $212.1M | Larger Scale | LCTX |
| Trailing P/E Ratio Valuation | N/M | 30.7x | Lower Multiple | LCTX |
| Forward P/E Ratio Valuation | N/M | 30.7x | Lower Multiple | LCTX |
| Revenue Growth (YoY) Growth | -46.5% | -61.0% | Higher Growth | VTGN |
| Operating Margin (TTM) Profitability | -2543.1% | -280.3% | Higher Margin | LCTX |
| Net Profit Margin Profitability | 0.0% | 16.2% | Higher Margin | LCTX |
| Return on Equity (ROE) Capital Efficiency | -144.9% | 4.3% | Higher ROE | LCTX |
| 52-Week Range Position Momentum | 0% ($0โ$5) | 4% ($1โ$2) | Stronger Trend | LCTX |
| Beta / 30D Volatility Risk Regime | 1.23ฮฒ ยท 80% Vol | 1.36ฮฒ ยท 79% Vol | Lower Realized Risk | LCTX |
| Unified Institutional Score Composite Signal | 42.3 / 100 (HOLD) | 58.9 / 100 (HOLD) | Higher Composite | LCTX |